Article
Targeting FOXA1-mediated repression of TGF-β signaling suppresses castration-resistant prostate cancer progression
4 Dec 2018
Abstract excerpt
Prostate cancer (PC) progressed to castration resistance (CRPC) is a fatal disease. CRPC tumors develop resistance to new-generation antiandrogen enzalutamide through lineage plasticity, characterized by epithelial-mesenchymal transition (EMT) and a basal-like phenotype. FOXA1 is a transcription factor essential for epithelial lineage differentiation. Here, we demonstrate that FOXA1 loss leads to remarkable...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
